NEW YORK – Fore Therapeutics' investments in its next-generation BRAF inhibitor plixorafenib seem to be paying off, as the company announced positive results from an interim analysis of its ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback